Literature DB >> 19878733

Effects of inhaled nitric oxide and surfactant with extracorporeal life support in recovery phase of septic acute lung injury in piglets.

Junfeng Song1, Kenneth Palmer, Bo Sun.   

Abstract

BACKGROUND: To improve survival from septic acute lung injury (ALI), extracorporeal life support (ECLS) is one of the ultimate solutions. We evaluated biochemical and pathological characteristics of recovery phase of septic ALI treated in acute phase by inhaled nitric oxide (NO) and surfactant with ECLS and hypothesized that this combination should exert better lung protective effects than that with conventional mechanical ventilation (CMV).
METHODS: ALI was induced by i.v. endotoxin and 4-6h CMV in young piglets (9-14kg) followed by treatment protocol for 24h in 4 modalities (n=5): VENT, CMV only; VNOS, VENT plus inhaled NO (10ppm) and surfactant (50mg/kg); ECMO, a veno-venous by-pass as extracorporeal membrane oxygenation; ENOS, ECMO plus inhaled NO and surfactant. After treatment they were weaned and maintained for recovery until day 7, and their lungs were processed for assessment of injury and reparation.
RESULTS: Plasma interleukin-8 levels in ENOS were lower than ECMO. On day 7 mRNA expression of inducible NO synthase and nitrite/nitrate levels in BALF were higher in VENT than in ECMO, interleukin-8 mRNA expression and lung apoptosis were lower in ENOS than in ECMO; disaturated phosphatidylcholine and mRNA expression of hepatocyte growth factor were higher, interleukin-8 content, NO synthase mRNA expression and malondialdehyde in lung tissue were lower, and morphologically lung injury and apoptosis were milder, in ENOS than in VENT.
CONCLUSIONS: ECLS combined with inhaled NO and surfactant alleviated septic injury and facilitated reparation in the lung recovery in contrast to CMV or ECMO alone. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19878733     DOI: 10.1016/j.pupt.2009.10.012

Source DB:  PubMed          Journal:  Pulm Pharmacol Ther        ISSN: 1094-5539            Impact factor:   3.410


  6 in total

1.  Extracorporeal membrane oxygenation improves survival in a novel 24-hour pig model of severe acute respiratory distress syndrome.

Authors:  Joaquín Araos; Leyla Alegría; Patricio García; Felipe Damiani; Pablo Tapia; Dagoberto Soto; Tatiana Salomon; Felipe Rodriguez; Macarena Amthauer; Benjamín Erranz; Gabriel Castro; Pamela Carreño; Tania Medina; Jaime Retamal; Pablo Cruces; Guillermo Bugedo; Alejandro Bruhn
Journal:  Am J Transl Res       Date:  2016-06-15       Impact factor: 4.060

2.  Effects of Vascular Endothelial Growth Factor in Recovery Phase of Acute Lung Injury in Mice.

Authors:  Junfeng Song; Hui Lu; Xuyang Zheng; Xianmei Huang
Journal:  Lung       Date:  2015-09-28       Impact factor: 2.584

3.  Inhaled NO contributes to lung repair in piglets with acute respiratory distress syndrome via increasing circulating endothelial progenitor cells.

Authors:  Yuanyuan Qi; Liling Qian; Bo Sun; Lijuan Liu; Panpan Wu; Libo Sun
Journal:  PLoS One       Date:  2012-03-20       Impact factor: 3.240

4.  Effects of pumpless extracorporeal lung assist on hemodynamics, gas exchange and inflammatory cascade response during experimental lung injury.

Authors:  Zhihai Ju; Jinhui Ma; Chen Wang; Jie Yu; Yeru Qiao; Feilong Hei
Journal:  Exp Ther Med       Date:  2017-12-18       Impact factor: 2.447

Review 5.  Extracorporeal membrane oxygenation (ECMO) and the acute respiratory distress syndrome (ARDS): a systematic review of pre-clinical models.

Authors:  Jonathan E Millar; Nicole Bartnikowski; Viktor von Bahr; Maximilian V Malfertheiner; Nchafatso G Obonyo; Mirko Belliato; Jacky Y Suen; Alain Combes; Daniel F McAuley; Roberto Lorusso; John F Fraser
Journal:  Intensive Care Med Exp       Date:  2019-03-25

Review 6.  Endothelial Damage in Acute Respiratory Distress Syndrome.

Authors:  Alice G Vassiliou; Anastasia Kotanidou; Ioanna Dimopoulou; Stylianos E Orfanos
Journal:  Int J Mol Sci       Date:  2020-11-20       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.